FDA delays PDUFA date for Rocket’s rare white blood cell disorder gene therapy
The FDA’s decision on Rocket Pharmaceuticals’ autologous gene therapy for a rare white blood cell disorder has been pushed back by three months to June …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
